Shares of the biopharmaceutical company Viking Therapeutics surged 21% on Thursday, October 24. The gains were attributable to released financial results for the third quarter, which showed that the company had sufficient financial resources to continue clinical trials for its promising weight-loss pill. If they are successful, Viking could eventually challenge current market leaders Novo Nordisk and Eli Lilly. Recall that earlier this month, Morgan Stanley included Viking in a list of small-cap stocks with at least 50% upside.

#Viking Therapeutics: 1

Potential Eli Lilly and Novo Nordisk competitor surges 21% on third-quarter financials